Fundraising FoxAMR Action Fund — Full Portfolio
22 tracked investments · listed companies and verified rows first
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona
Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)inMarina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Co-investorsBaruch Future VenturesNSG VenturesOrbiMedSBI JI Innovation Advisory Ltd.Seventure Partners8VC+2 more
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.
BiotechHealthtech
Marc Lemonnier(Chief Executive Officer)inRienk Pypstra(Chief Medical Officer)Gordon Waldron(Chief Financial Officer)inMagdalena Zalacain(Chief Scientific Officer)in
Co-investorsBNP Paribas DéveloppementIRDI SORIDEC GestionOmnes Capital
Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsNCL Technology Ventures Ltd.Boehringer Ingelheim Venture Fund
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)inCarey-Ann Burnham(Chief Executive Officer)inTravis Davies(SVP, Operations)inKyle Fieleke(SVP, Corporate Development & Finance)inDavid Bussian(SVP, Clinical, Regulatory & Assay Development)in
Co-investorsIllumina VenturesIllumina Innovation
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in
BoardJonathan Leff(Director)inEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsHackensack Meridian Health Bear's DenMaryland TEDCOTEDCODeerfield Management CompanySofinnova Ventures
Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.
BiotechNew York, US
Kieren Marr(Executive Officer, Director)
BoardJim Flynn(Director)Jonathan Leff(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsIllinois VenturesDeerfield Management Company
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsDelos CapitalVivo CapitalBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)inDaniel Couto(Executive Officer)inMark Mullikin(Executive Officer)inJeffrey Silber(Executive Officer)inChristopher Viehbacher(Director)
BoardJohn LaMattina(Director)in
Board seatMartin Heidecker· per SEC Form D
Co-investorsColorcon VenturesK2 HealthVenturesSalica InvestmentsSeventure PartnersBNP ParibasBNP Paribas Asset Management Europe+2 more
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
BiotechMalvern, US
Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsBioAdvanceForesite CapitalVersant Ventures
BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections.
BiotechDeep TechHealthtechMedical DevicesBasel, CH
Dr. Marc Gitzinger(Chief Executive Officer & Founder)
Co-investorsStartAngels Network
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAstellas Venture Management LLCBrace PharmaSofinnova PartnersSunstone Capital+4 more
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Co-investorsDolby Family VenturesEpidarex CapitalBoehringer Ingelheim Venture Fund
Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections.
BiotechHealthtechMedical DevicesPittsburg, US
Jonathan Steckbeck(Founder)in
BoardStephan Dietrich(Director)in
Co-investorsAAF Management Ltd.Alpha Wave GlobalBright Success CapitalGaingelsMana VenturesMountain State Capital+8 more
__Twitter.png)
Telum Therapeutics develops antimicrobial drugs using synthetic biology and AI-driven machine learning, specializing in engineered lytic proteins to address multidrug-resistant infections.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesNoáin, ES
Subhendu Basu(Chief Executive Officer)inRoberto Díez(Chief Operating Officer)inDiana Gutiérrez(Chief Scientific Officer)in
Co-investorsInvivo Capital PartnersClaveClave Capital
Trellis is an AI-driven platform that automates advertising, pricing, and profitability optimization for eCommerce sellers on marketplaces like Amazon, Walmart, and Shopify.
AdTechAI & Machine LearningE-commerceOttawa, CA
Denis Leclair(Founder)inFahim Sheikh(Founder)in
Co-investorsOkapi Venture CapitalSentiero VenturesCraft VenturesEaston CapitalNew Science VenturesStout Street Capital
Trellis Health provides personalized health insights that track individual changes over time rather than comparing against population norms.
Digital HealthFemTechHealthtech
Co-investorsNextbluePALETTE VENTURESSwizzle VenturesEaston CapitalNew Science Ventures
Trellis is a fintech company operating in Pakistan that provides financial inclusion solutions and digital transformation services.
Digital HealthFintechImpact & Social GoodPropTechPakistan, PK
Sohail Hasnie(CEO)
Co-investorsGobi PartnersInsitorTPL E VenturesEaston CapitalNew Science Ventures
Trellis Bioscience develops human monoclonal antibody therapeutics targeting bacterial, viral, and cancer indications.
BiotechHealthtechRedwood City, US
Larry Kauvar(Chief Science Officer)Stefan Ryser(President and Chief Executive Officer)inGeoff Dillon(Chief Business Officer)inElisabeth Whitney(Chief Operating Officer)Nora Mende(Chief Financial Officer)
Co-investorsEaston CapitalNew Science Ventures
Obtained U.S.
Co-investors3B Future Health Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abexxa BiologicsTenNor TherapeuticsTennorx
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.